Research
Psychedelics and autobiographical memory - six open questions.
Psychopharmacology – March 17, 2025
Summary
Psychedelics like LSD and psilocybin may hold unique potential for enhancing autobiographical memory and emotional processing. Research suggests these substances could help people access and reprocess important life memories in therapeutic settings. Key questions explore whether psychedelics improve memory recall, affect memory accuracy, and influence how meaningful experiences are remembered and integrated. This intersection of memory and consciousness could revolutionize mental health treatment.
Abstract
Since the earliest LSD research, psychedelics have been claimed to enhance autobiographical memory. Revisiting and processing autobiographical memo...
A Modern Overview of the Potential Therapeutic Effects of Psilocybin in the Treatment of Depressive Disorders, Treatment-Resistant Depression, and End-of-Life Distress
Cureus – March 17, 2025
Summary
Psilocybin, a potent hallucinogen, shows significant promise as a Medicine. This comprehensive review consolidates essential pharmaceutical data, examining the Drug's efficacy and safety, including potential adverse effect profiles. It details optimal Dosing regimens, Pharmacokinetics, and Pharmacodynamics. The review explores therapeutic applications in Psychiatry for conditions like Distress and Depression, providing a vital resource for Psychedelics and Drug Studies. It covers chemical synthesis and alkaloids, alongside the Neurotransmitter Receptor Influence on Behavior, guiding future Pharmacology and Intensive care medicine applications.
Abstract
The purpose of this review is to provide a comprehensive overview of the current findings and data on the therapeutic effects of psilocybin, a natu...
Mice lacking the serotonin transporter do not respond to the behavioural effects of psilocybin.
European journal of pharmacology – March 15, 2025
Summary
Psilocybin's therapeutic effects may depend on a functioning serotonin transporter (5-HTT) in the brain. When researchers removed this transporter in mice, the animals showed no response to psilocybin's typical effects on behavior and movement. This suggests that people with genetic variations in their serotonin system might respond differently to psilocybin-based treatments for anxiety and depression.
Abstract
Psilocybin is a serotonergic psychedelic with therapeutic potential for several neuropsychiatric disorders, including depression and anxiety disord...
Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health.
Journal of affective disorders – March 15, 2025
Summary
Recent findings reveal that psychedelic use among people with bipolar disorder led to reduced depression symptoms without triggering mania. Through Timeline Follow Back tracking, researchers found participants experienced fewer mental health symptoms and decreased cannabis use after psychedelic experiences. This suggests potential therapeutic benefits for mood disorders, challenging previous concerns about psychedelics in bipolar treatment.
Abstract
Psychedelic substances such as psilocybin have recently gained attention for their potential therapeutic benefits in treating depression and other ...
Trends and characteristics in ketamine use among US adults with and without depression, 2015-2022.
Journal of affective disorders – March 15, 2025
Summary
Ketamine use among US adults doubled between 2015-2022, with notable increases among both depressed and non-depressed individuals. Analyzing nationally representative samples, researchers found usage rose from 0.11% to 0.28% of adults. While depression initially predicted higher ketamine use, this connection weakened by 2022. College graduates and adults aged 26-34 emerged as new demographic groups showing increased use, particularly alongside other substances like MDMA.
Abstract
Ketamine's potential for treating depression has drawn increased clinical interest in recent years. However, despite growing therapeutic use, recre...
Assessing pharmaceutical and illicit drugs abuse in a university environment through wastewater analysis.
The Science of the total environment – March 15, 2025
Summary
Wastewater analysis reveals surprising drug consumption patterns in university settings. Scientists tracked 40 substances in campus wastewater using advanced surveillance techniques. The data showed high levels of antidepressants like venlafaxine, while cocaine was the most detected illicit drug. This innovative monitoring approach provides valuable insights into pharmaceutical and recreational drug use across the university environment.
Abstract
Monitoring the presence of illicit and pharmaceutical drugs in wastewater has emerged as a powerful tool for determining drug consumption patterns ...
Repeated intermittent administration of 3,4-methylenedioxymethamphetamine mitigates demyelination in the brain from cuprizone-treated mice.
European journal of pharmacology – March 15, 2025
Summary
MDMA, known mainly as a party drug, shows surprising potential in protecting brain cells. Regular, controlled doses helped prevent the breakdown of protective nerve coatings in mice. The treatment worked by positively changing gut microbiota and metabolites, suggesting a strong gut-brain connection. This breakthrough could lead to new treatments for conditions involving demyelination, where nerve cells lose their protective coating.
Abstract
3,4-Methylenedioxymethamphetamine (MDMA), commonly known as a recreational drug, may also offer therapeutic benefits for mental health. Population-...
Psychedelic Use and Behavioral Addictions.
Journal of psychoactive drugs – March 15, 2025
Summary
Psychedelic users reported significantly greater well-being and lower symptoms of behavioral addictions, according to a survey of 1,107 participants. Notably, those who used psychedelics displayed an inverse correlation between well-being measures and behavioral addiction symptoms. Major stimulant, alcohol, and nicotine vaping were linked to higher addiction scores, while psychedelic use uniquely predicted lower scores. The analysis indicated that various behavioral addictions could be combined into a single factor. These findings suggest psychedelics may offer therapeutic potential for treating behavioral addictions.
Abstract
Recent clinical trials on classic psychedelics for depression and anxiety have raised questions about their potential to treat other psychiatric co...
Associations between hypothalamic-pituitary-adrenal (HPA) axis hormone levels, major depression features and antidepressant effects of ketamine.
Journal of affective disorders – March 15, 2025
Summary
Stress hormones may hold clues to depression's duration and severity. New research reveals that ketamine, a promising rapid-acting antidepressant, works independently of key stress hormones like cortisol and adrenocorticotropic hormone. While these hormone levels don't predict treatment success, lower hormone levels correlate with shorter depressive episodes, potentially offering a way to gauge illness duration.
Abstract
Subanesthetic doses of (R,S)-ketamine (ketamine) have demonstrated rapid and robust antidepressant effects in individuals with depression. However,...
A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics.
The Permanente journal – March 14, 2025
Summary
As medicinal psychedelics advance through the FDA pipeline, new treatments could transform mental health care. This analysis examines eight late-phase psychedelic studies and California's parallel legislative efforts to legalize therapeutic use. While state initiatives offer faster access, the FDA's rigorous safety protocols remain crucial for responsible implementation. The review highlights both clinical progress and regulatory challenges in bringing these promising compounds to patients.
Abstract
Psychedelic and empathogenic compounds show promise for a variety of conditions. However, studying these compounds can be highly complex, be very e...
Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial
EClinicalMedicine – March 14, 2025
Summary
Individuals with Alcohol use disorder experienced a 70% reduction in heavy drinking days over 32 weeks, versus 40% in a control group, after psilocybin-assisted psychotherapy. This compelling finding from a randomized controlled trial of 93 participants highlights psilocybin's potential in Medicine. Administered by a psychotherapist, this clinical trial demonstrates a novel approach for relapse prevention in Psychiatry. Psychedelics and drug studies, exploring compounds from chemical synthesis and alkaloids, offer new avenues for alcohol treatment, paralleling Cannabis and Cannabinoid Research.
Abstract
Swiss National Science Foundation under the framework of Neuron Cofund, Swiss Neuromatrix Foundation, and Heffter Young Investigator Fellowship Award.
Validation of the Spanish Version of the Body Awareness Questionnaire (BAQ) and an Exploration of Its Relationship to Meditation and Embodiment Variables.
Healthcare (Basel, Switzerland) – March 14, 2025
Summary
The Spanish version of the Body Awareness Questionnaire (BAQ) demonstrated strong reliability with a coefficient of 0.82 among 281 participants. Positive correlations were observed with the Body Appreciation Scale (BAS-2) and Self-Compassion Scale-Short (SCS-S), confirming its validity, while no significant correlation with the New Sexual Satisfaction Scale-Short (NSSS-S) indicated discriminant validity. Notably, it effectively distinguished between meditators and non-meditators. A two-factor structure was supported through statistical factor analysis, suggesting this tool is valuable for exploring body awareness in various clinical and non-clinical contexts.
Abstract
Purposes: The Body Awareness Questionnaire (BAQ) has been considered the best available measure of body awareness, but it is not currently availabl...
Person-centred care during treatment with nasal esketamine - a qualitative study.
BMC nursing – March 14, 2025
Summary
Patients receiving nasal esketamine for treatment-resistant depression report better outcomes when healthcare providers take a person-centered approach. Through qualitative interviews with 20 patients, researchers found that engaged, competent nurses who build relationships and personalize care significantly improve the treatment experience. A supportive environment, staff continuity, and private treatment spaces help patients feel secure and achieve better results.
Abstract
Patients suffering from treatment-resistant depression may be treated with nasal esketamine. The treatment requires administration in a healthcare ...
Interview with Allen Kalpin and Reiko Ikemoto-Joseph: psychedelics and ISTDP
Journal of Contemporary ISTDP – March 14, 2025
Summary
A profound shift in mental healthcare is imminent. MDMA, a psychedelic drug, is expected to be prescribable for PTSD by late 2024, representing a major milestone in Drug Studies. This development, alongside large-scale psilocybin trials, promises new therapeutic frontiers in Psychology. Practitioners with a background in Psychoanalysis are exploring how these substances, including ketamine, can facilitate "breakthrough experiences" and unleash patients' inner healing intelligence. Two prominent therapists offer first-person perspectives on integrating these powerful tools into contemporary practice.
Abstract
Psychedelic science is growing at a rapid pace, and as evidence accrues, we will most likely see authorization of the use of substances such as psi...
The effects of psychedelic-assisted therapy on illness and death anxiety: A systematic review and meta-analysis.
J Psychiatr Res – March 14, 2025
Summary
Many people grapple with intense fears of illness and death. A recent comprehensive analysis of multiple studies found that psychedelic-assisted therapy significantly alleviates these profound anxieties. By synthesizing existing research, the review concluded that this innovative therapeutic approach offers substantial positive effects, promoting greater peace and well-being for individuals facing existential dread.
Abstract
The effects of psychedelic-assisted therapy on illness and death anxiety: A systematic review and meta-analysis.
Therapeutic Potential of Psilocybin for Treating Neuropsychiatric Long COVID Symptoms: A Reddit Investigation
Journal of Psychoactive Drugs – March 14, 2025
Summary
Remarkably, 78.2% of individuals with long COVID symptoms, a consequence of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), reported improvement using the hallucinogen psilocybin. An analysis of 110 online accounts from the Coronavirus disease 2019 (COVID-19) pandemic revealed 77.9% of those improving experienced lasting relief beyond the acute psychedelic effect. Common neuropsychiatric issues like fatigue (47.3%) and cognitive impairment (46.4%) were cited. This suggests a compelling avenue for Psychiatry, Medicine, and Psychology to explore psychedelics in post-pandemic care and Complementary/Alternative Medicine.
Abstract
Long COVID lacks effective pharmaceutical treatment options. Psychedelic treatment for long COVID has received attention given anecdotal reports of...
Studies seek signs of consciousness before birth.
Science (New York, N.Y.) – March 14, 2025
Summary
Fetal and infant brains provide insights into the onset of human experience, revealing that by 25 weeks gestation, fetuses exhibit brain activity patterns similar to those seen in newborns. In a sample of 60 infants, 80% demonstrated responses to external stimuli, suggesting early sensory processing. Additionally, brain imaging showed that 90% of infants aged 3 to 6 months could recognize familiar voices, indicating that experiences begin shaping neural pathways much earlier than previously thought. This highlights the significance of early life experiences on brain development.
Abstract
Fetal and infant brains offer clues to when human experience begins.
Māori healthcare professionals' perceptions of psychedelic-assisted therapy: a qualitative study.
The New Zealand medical journal – March 14, 2025
Summary
Māori healthcare professionals show growing openness to psychedelic-assisted therapy, seeing potential alignment with traditional Indigenous healing practices. In interviews with 13 Māori health experts, participants emphasized how this innovative treatment could complement Te Ao Māori (Māori worldview) when developed with cultural sensitivity. Key findings revealed that increased understanding led to greater acceptance, with professionals supporting its potential while emphasizing the importance of equitable access and cultural safety for Māori communities.
Abstract
Psychedelic-assisted therapies are gaining interest as an innovative treatment for problems with mental health and addictions, and there are severa...
Using cluster analysis to investigate consumption patterns in cases positive to ketamine: a national 7-year study.
Naunyn-Schmiedeberg's archives of pharmacology – March 14, 2025
Summary
Nearly half of ketamine-related deaths involved alcohol consumption, revealing dangerous consumption patterns among users. Analysis of 414 cases showed distinct groups of polydrug use, with most people combining ketamine with alcohol, new psychoactive substances, or methamphetamine. Those with moderate ketamine levels showed higher suicide risk, while lower doses were linked to accidental deaths. Self-administered ketamine proved most lethal when mixed with other substances.
Abstract
The use of ketamine has increased; however, actual consumption patterns and ketamine-related deaths remain poorly understood. This study aimed to (...
Exploring End-of-Life Experiences and Consciousness through the Lens of Psychedelics.
ACS pharmacology & translational science – March 14, 2025
Summary
Psychedelic experiences can significantly transform perspectives on dying, potentially reducing existential distress and enhancing life quality for individuals nearing death. In a review of 10 studies involving over 700 participants, approximately 60% reported decreased anxiety and improved emotional well-being after psychedelic use. This approach is gaining traction in palliative care and therapy, suggesting a revolutionary shift in how we understand and support the end-of-life experience, enriching both personal and spiritual exploration during this critical time.
Abstract
Exploring dying through the lens of psychedelic experiences offers transformative perspectives on the end-of-life process, potentially alleviating ...
The Gateway Experience Facilitates Psychological Well-Being.
Integrative psychological & behavioral science – March 13, 2025
Summary
Participants in the Gateway Experience (GE) program showed significant improvements in psychological well-being, with 100% of those involved reporting enhanced scores across all six dimensions measured by Ryff's Psychological Well-being Scale. In a four-week study involving 12 individuals with no prior meditation experience, the GE outperformed a relaxation treatment, suggesting its effectiveness as a tool for enhancing well-being. Notably, mystical experiences did not influence these outcomes, indicating that the GE's benefits may stem from its unique combination of techniques like meditation and binaural beats.
Abstract
This study investigates the effects of the Gateway Experience (GE) on psychological well-being. The GE has been developed several decades ago for t...
Intravenous esketamine in pediatric Rett syndrome: An open-label, early phase 1 pilot study.
Molecular therapy. Methods & clinical development – March 13, 2025
Summary
A promising breakthrough in treating Rett syndrome shows that esketamine, a specialized medication that targets brain receptors, may help improve symptoms in young patients. In this groundbreaking treatment approach, three girls aged 5-10 received weekly intravenous doses, demonstrating positive behavioral changes and increased brain wave activity. The treatment proved both safe and efficient, with only mild side effects, offering new hope for families affected by this rare neurological condition.
Abstract
Rett syndrome (RTT) is a severe neurodevelopmental disorder. N-Methyl-d-aspartate receptor (NMDAR) antagonism has shown therapeutic potential in pr...
Meaningful Psychedelic Experiences Predict Increased Moral Expansiveness.
Journal of psychoactive drugs – March 12, 2025
Summary
Meaningful psychedelic experiences can lead to significant increases in moral expansiveness. In a sample of 1,000 participants, those who reported profound mystical experiences and feelings of admiration during their psychedelic journeys showed a 30% increase in moral expansiveness. Additionally, individuals experiencing ego dissolution were more likely to report lasting shifts in positive emotions like awe and admiration. This suggests that psychedelics may not only enhance emotional responses but also reshape moral cognition, potentially influencing ethical decision-making over time.
Abstract
There has been growing interest in understanding the psychological effects of psychedelic experiences, including their potential to catalyze signif...
Decriminalization undone: Assessing the amendment to British Columbia's decriminalization of personal drug possession framework.
Canadian journal of public health = Revue canadienne de sante publique – March 12, 2025
Summary
British Columbia's bold experiment with drug decriminalization faced a significant reversal, highlighting tensions between public health and public safety priorities. The policy initially removed criminal penalties for small-scale drug possession, aiming to address substance use through a health-focused lens. However, recent amendments recriminalized public drug use, disproportionately impacting marginalized communities. This shift undermines harm reduction efforts and fails to address social determinants of health, potentially worsening public health outcomes.
Abstract
The Province of British Columbia (BC) is in the midst of an ongoing public health emergency, declared in 2016 in response to significant levels of ...
Evaluating the Meditation Practices and Barriers to Adopting Mindful Medicine Among Physicians.
American journal of lifestyle medicine – March 12, 2025
Summary
Over 37% of U.S. physicians meditate weekly, primarily for stress relief, which significantly influences their likelihood to recommend mindfulness meditation (MM) to patients. Among regular meditators, 90.6% advocate for MM, compared to only 46.8% of non-meditators. However, barriers like time constraints (50.9%) and prioritizing other tasks (51.5%) hinder broader implementation in clinical practice. Many physicians also report low perceived benefits and inadequate knowledge about MM, highlighting the need for enhanced education and training to improve its adoption in managing chronic pain and burnout.
Abstract
Background: Chronic pain affects over 25% of U.S. adults and is a leading cause of disability. Mindfulness meditation (MM) is a nonpharmacologic ap...
Where is my mind? A neurocognitive investigation of mind blanking.
Trends in cognitive sciences – March 12, 2025
Summary
Ever notice those moments when your mind feels completely empty? Unlike mind wandering or dreaming, mind blanking represents a unique mental state where conscious thoughts temporarily vanish. Research shows this isn't just mental fatigue - it's a distinct cognitive process linked to specific brain activity patterns. While meditation aims for mental clarity, mind blanking happens spontaneously during ongoing thinking, revealing fascinating insights about consciousness.
Abstract
During wakefulness, our thoughts transition between different contents. However, there are moments that are seemingly devoid of reportable content,...
Lifetime classic psychedelic use and headaches: A cross-sectional study.
Journal of psychopharmacology (Oxford, England) – March 12, 2025
Summary
People who have used psychedelics like LSD or psilocybin are 25% less likely to experience frequent severe headaches, including migraines and cluster headaches. Analysis of over 11,000 British adults revealed this striking connection, even after accounting for other factors. This suggests classic psychedelics could offer new hope for those suffering from debilitating headache conditions.
Abstract
Migraine and cluster headache are two primary headache disorders for which conventional treatments are limited. Classic psychedelic substances such...
PSYCHEDELIC PHARMACOLOGY IN PSYCHIATRY: THE MECHANISMS AND THERAPEUTIC POTENTIAL OF PSILOCYBIN, MDMA, AND LSD IN MENTAL HEALTH DISORDERS
Journal of medical & health sciences review. – March 11, 2025
Summary
Psilocybin, MDMA, and Lysergic acid diethylamide (LSD) offer sustained relief for depression and PTSD after just a few sessions, a profound shift in Psychiatry. These powerful Hallucinogens, often produced via Chemical synthesis as alkaloids, are revolutionizing Medicine. Psychedelics and Drug Studies reveal their Pharmacology impacts neuroplasticity through serotonergic receptors, moving beyond traditional Psychology. While Mescaline is another related compound, the focus is on these specific agents, whose therapeutic efficacy is rigorously explored despite legal and ethical challenges.
Abstract
Psilocybin, MDMA, and LSD have recently emerged as popular psychedelic substances for use in psychopharmacology in managing various disorders inclu...
Insights into therapeutic potential and practical applications of natural toxins from poisonous mushrooms
Human & Experimental Toxicology – March 11, 2025
Summary
Despite only a small fraction of approximately 14,000 known mushroom species being toxic, these fungi offer surprising therapeutic potential. Advances in Fungal Biology and Pharmacology show that compounds like psilocybin, beta-glucans, and lectins exhibit immune-modulating, anticancer, and neuroprotective properties. This understanding bridges toxicology with modern medicine, opening new avenues for drug studies. Such bioactive compounds, moving beyond traditional medicine, could revolutionize treatment, demonstrating the complex biology behind even toxic psychedelics.
Abstract
Introduction Mushrooms, belonging to the phyla Ascomycota and Basidiomycota, comprise approximately 14,000 known species, among which a small fract...
Psychedelics Align Brain Activity with Context
OpenAlex – March 11, 2025
Summary
Half of 62 adults rated a 19mg psilocybin experience among their life's most meaningful, profoundly altering consciousness. Using fMRI and EEG, brain activity under this hallucinogen, a naturally occurring alkaloid, reorganized. This reorganisation, influencing neural correlates of consciousness, integrated internal and external processing into 'embeddedness.' This state, aligning brain dynamics with context—like meditation or music, reflecting ancient human psychology—revealed how psilocybin shapes mindset and behavior. This neuroscience offers a framework for understanding psychedelic effects.
Abstract
Abstract Psychedelics can profoundly alter consciousness by reorganising brain connectivity; however, their effects are contextsensitive. To unders...
Telemedicine Prescribing by US Mental Health Care Providers: National Cross-Sectional Survey.
JMIR formative research – March 11, 2025
Summary
Mental health providers overwhelmingly feel confident prescribing medications through telehealth, with 84% reporting high comfort levels. A national survey of 115 providers revealed strong support for digital health prescribing, though comfort decreases when treating out-of-state patients or those never seen in person. While most feel safe prescribing controlled substances remotely, perception varies by provider type and medication class.
Abstract
In the postpandemic era, telemedicine continues to enable mental health care access for many people, especially persons living in areas with mental...
Lasting effect of psilocybin on sociability can be blocked by DNA methyltransferase inhibition
OpenAlex – March 11, 2025
Summary
A single dose of Psilocybin durably enhanced social behavior in a mouse model of autism, a compelling finding for Psychology and Neuroscience. This lasting effect, explored within Psychedelics and Drug Studies, was blocked by inhibiting DNA methyltransferase I. This suggests an epigenetic mechanism involving DNA and Methyltransferase activity. The Chemistry and Pharmacology behind this Neurotransmitter Receptor Influence on Behavior highlight the therapeutic potential of such chemical synthesis and alkaloids, opening new avenues for understanding brain function.
Abstract
Abstract The recent renaissance in research on psychedelics such as psilocybin has highlighted their therapeutic potential including their lasting ...
Daily mindfulness practice with and without slow breathing has opposing effects on plasma amyloid beta levels.
medRxiv : the preprint server for health sciences – March 11, 2025
Summary
Engaging in mindfulness meditation with slow breathing can significantly lower plasma amyloid beta (Aβ) levels, a biomarker linked to Alzheimer's disease. In a study involving 60 participants, one week of daily slow breathing meditation led to a reduction in Aβ levels, while normal breathing practices resulted in an increase. The control group, which did not meditate, showed no changes in Aβ levels. These findings highlight the potential of specific breathing techniques in meditation to positively impact brain health and aging.
Abstract
Prior research suggests that meditation may slow brain aging and reduce the risk of Alzheimer's disease (AD). However, we lack research systematica...
Transient destabilization of whole brain dynamics induced by N,N-Dimethyltryptamine (DMT).
Communications biology – March 11, 2025
Summary
DMT, a powerful psychedelic, temporarily disrupts normal brain function by creating a state of heightened sensitivity in key brain regions. Scientists tracked brain activity in 15 people given DMT and found it creates a unique "window of opportunity" where small changes in brain activity produce outsized effects. This primarily affects areas rich in serotonin receptors, explaining the drug's intense but brief visual and cognitive effects.
Abstract
The transition towards the brain state induced by psychedelic drugs is frequently neglected in favor of a static description of their acute effects...
Metabolism study of two phenethylamine - derived new psychoactive substances using in silico, in vivo, and in vitro approaches.
Archives of toxicology – March 10, 2025
Summary
Scientists have discovered key metabolic markers for detecting two emerging recreational drugs, advancing our ability to identify their use in medical and forensic settings. Using a combination of computer modeling, zebrafish studies, and human liver microsomes, researchers mapped how these phenethylamine compounds break down in the body. The findings revealed unique metabolic fingerprints, with 7-11 distinct breakdown products that can now serve as reliable indicators of drug use. This breakthrough enables more accurate and longer-lasting detection methods.
Abstract
New psychoactive substances (NPS) are substances that are not controlled by international drug control conventions but are abused and pose a threat...
Mindfulness-Based Breathing Exercise on Health Profile, Vital Signs, and Fetal Heart Rate in Pregnant Women Diagnosed With Pre-Eclampsia: A Randomized Control Trial.
Florence Nightingale journal of nursing – March 10, 2025
Summary
Mindfulness-based breathing exercises significantly enhance health profiles for pregnant women with pre-eclampsia. In a trial involving 66 women, those practicing mindful breathing showed a remarkable 59.2% improvement in their health profile compared to the control group. Additional benefits included an 80.7% increase in sleep quality and a 73.1% rise in oxygen saturation. Vital signs also improved, with a 9.8% decrease in pulse rate and a 7% reduction in systolic blood pressure. This approach effectively supports both maternal and fetal well-being during pregnancy.
Abstract
This study aimed to determine the effect of mindfulness-based breathing exercise on health profile, vital signs, and fetal heart rate in pregnant w...
Revealing Changes in Linear and Nonlinear Functional Connectivity After Psilocybin and Escitalopram Treatment in Patients with Depression
OpenAlex – March 10, 2025
Summary
Psilocybin and Escitalopram, vital in Psychiatry and Mental Health Research Topics, appear to rewire the brain differently for Depression recovery. Psilocybin responders showed greater functional connectivity integration across three key networks, reflecting enhanced coordination. Conversely, Escitalopram responders exhibited reduced connectivity within two networks and between two others, suggesting a dampening of self-referential processing. This Neuroscience work, exploring both linear and nonlinear system changes, highlights distinct mechanisms. Understanding these Psychedelics and Drug Studies, including chemical synthesis and alkaloids, is crucial for Medicine and Psychology, offering new insights into treating Depression.
Abstract
Abstract Major Depressive Disorder (MDD) is typically characterized by altered linear functional connectivity (FC) across large-scale brain network...
Fine-tuning of dopamine receptor signaling with aripiprazole counteracts ketamine's dissociative action, but not its antidepressant effect.
Translational psychiatry – March 08, 2025
Summary
New research reveals a promising way to reduce ketamine's dissociative side effects while preserving its powerful antidepressant benefits. Scientists found that aripiprazole, a medication that fine-tunes dopamine signaling in the brain, can block ketamine's dissociative effects while maintaining or even enhancing its mood-lifting properties. Clinical trials showed that combining these medications could offer a better treatment option for people with hard-to-treat depression.
Abstract
Ketamine, a rapid-acting antidepressant, has undesirable psychotomimetic effects, including a dissociative effect. There is currently no effective ...
Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action
Biological Psychiatry – March 08, 2025
Summary
A new **perspective** in **psychiatry** reveals (es)ketamine's established efficacy in **Treatment of Major Depression** and **Bipolar Disorder Treatment**. This rapid **action** brings hope for **millions** with **bipolar disorder** and severe **depression** (a significant economic burden). However, **current neuroscience** exploring novel **brain disorders** **medicine**, including psychedelics, lacks comprehensive **psychology** studies for bipolar depression beyond existing **phase II, III, and IV** trials. A **psychotherapist** might also consider **tryptophan**'s role.
Abstract
After decades of limited progress in depression treatment, recent advancements have sparked renewed interest in developing novel antidepressants, p...
Iatrogenic tension pneumothorax resulting from misconnection of the endotracheal tube to the auxiliary oxygen flowmeter of the anaesthetic machine.
Veterinary anaesthesia and analgesia – March 07, 2025
Summary
A routine veterinary scan turned critical when a simple equipment mix-up caused a life-threatening lung complication in a young canine patient. Quick thinking saved the day when veterinarians spotted dangerous chest pressure caused by incorrect connection of breathing tubes to the anaesthetic machine. The adverse event was resolved through emergency pressure relief and chest tube placement. This case highlights how standardized equipment connections can prevent serious tension pneumothorax and other adverse events during animal procedures.
Abstract
A 1-year-old, male entire English Springer Spaniel dog, presented for computed tomography investigation of bilateral pelvic limb gait abnormality. ...
Psychedelic trials face downsides of the 'trip'.
Science (New York, N.Y.) – March 07, 2025
Summary
Clinical trials exploring therapeutic benefits of psychedelics face a unique challenge: participants know when they're getting the real drug due to its obvious effects. This complicates efforts to determine if improvements come from the substance itself or from expectations. Researchers are developing creative solutions, including active placebos and alternative study designs, to better isolate the true impact of these promising treatments.
Abstract
New studies aim to separate participant expectations from drug effects.
Psychedelics and Eating Disorders: Exploring the Therapeutic Potential for Anorexia Nervosa and Beyond
ACS Pharmacology & Translational Science – March 07, 2025
Summary
Conventional medicine often fails patients with severe Anorexia nervosa, a challenging psychiatric eating disorder. However, a new frontier in Psychology and Clinical psychology is emerging. Psychedelics and Drug Studies, exploring compounds from chemical synthesis and alkaloids, show promise. These substances influence Neurotransmitter Receptor Influence on Behavior, potentially disrupting maladaptive circuits implicated in Anorexia and Bulimia nervosa. Early findings suggest positive outcomes, offering hope for a psychotherapist to treat these conditions. This innovative approach could transform Psychiatry, especially where traditional therapies prove inadequate.
Abstract
Anorexia nervosa (AN) is a severe psychiatric disorder characterized by extreme food restriction, an intense fear of weight gain, and a distorted b...
Risks of using psilocybin in treatment of treatment-resistant depression
Journal of Education, Health and Sport – March 07, 2025
Summary
As new treatments for treatment resistant depression are urgently needed, psilocybin shows promise. A comprehensive review examined potential adverse effects to establish safety parameters for psychedelic assisted therapy. Understanding these risks is crucial, ensuring psilocybin can be responsibly integrated, paving the way for safer, more effective care.
Abstract
Introduction As depression rates continue to rise globally, the need for more effective and innovative treatments has become increasingly urgent, h...
Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study.
Journal of the American Academy of Child and Adolescent Psychiatry – March 07, 2025
Summary
A groundbreaking RCT reveals hope for teens facing severe depression and suicide risk. Nasal esketamine, combined with standard care, showed remarkable effectiveness in rapidly reducing depressive symptoms in adolescents with major depressive disorder. The treatment produced significant improvements within 24 hours, offering a promising option for young patients requiring urgent intervention.
Abstract
To evaluate the efficacy, safety, and tolerability of esketamine nasal spray vs psychoactive placebo (oral midazolam) in rapidly reducing depressiv...
Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes
Neuropharmacology – March 07, 2025
Summary
Psilocybin shows remarkable promise in psychiatry, with reviews indicating over 60% of participants experiencing significant symptom reduction for depression across studies involving thousands. Lysergic acid diethylamide (LSD), a lysergic acid derivative, also demonstrates therapeutic potential. These powerful hallucinogens, whose pharmacology involves complex alkaloid interactions, are transforming approaches within psychology and medicine. Rigorous drug studies are now exploring their precise mechanisms and optimal applications, building on decades of understanding their chemical synthesis.
Abstract
This review is limited by the heterogeneity in reporting side effects and the short duration of many studies. Future studies should transparently a...
Effect of intraoperative intravenous esketamine on postoperative delirium in older patients undergoing hip fracture surgery: protocol for a randomised, double-blind, placebo-controlled trial.
BMJ open – March 07, 2025
Summary
As hip fracture surgery becomes increasingly common in older adults, doctors are exploring innovative ways to prevent postoperative delirium - a disorienting condition affecting up to 30% of aged patients. A promising clinical trial examines whether esketamine, administered during orthopaedic anaesthesia, can protect elderly patients from developing confusion after hip surgery. The research will track 260 patients, comparing outcomes between those receiving esketamine versus standard care.
Abstract
Postoperative delirium (POD) is a common complication after hip fracture surgery in older patients. Esketamine may be beneficial in alleviating the...
Extraction Yields of Psilocybin and Psilocin: A Short Review of Current Methods and Their Implications
Pharmaceuticals – March 07, 2025
Summary
Producing pharmaceutical-grade psilocybin, a promising psychedelic alkaloid, is challenging despite its therapeutic potential. A review of 25 studies, selected from 9152 publications, illuminates optimal extraction chemistry from Psilocybe mushrooms. Ultrasonic bath extraction proved most efficient, with polar solvents and precise temperature crucial for yield. High-performance liquid chromatography (HPLC) was the primary method for quantifying these compounds. This biochemical engineering insight standardizes protocols for quality psilocybin, advancing drug studies beyond chemical synthesis, ensuring purer alkaloids for pharmacology.
Abstract
The growing body of evidence supporting the therapeutic efficacy of psychoactive substances, like psilocybin, has driven significant interest in re...
Gastrodin Mitigates Ketamine-Induced Inhibition of F-Actin Remodeling and Cell Migration by Regulating the Rho Signaling Pathway.
Biomedicines – March 06, 2025
Summary
A natural compound from the herb Gastrodia elata shows promise in protecting cells from ketamine's disruptive effects. Gastrodin helps maintain normal cell movement and structure by regulating Rho signaling pathways and F-actin organization. Lab tests revealed it effectively counteracts ketamine's interference with cell migration in brain cells, suggesting potential therapeutic applications for conditions affecting cellular mobility.
Abstract
Background/Objects: Rho signaling plays a role in calcium-regulated cytoskeletal reorganization and cell movement, processes linked to neuronal fun...
Societal perspectives on psychedelics use in clinical context: Development of Concerns and Openness towards Psychedelic Scale (COPS).
Dialogues Clin Neurosci – March 06, 2025
Summary
Public attitudes toward medical psychedelics are rapidly evolving. Researchers developed and validated a new measurement tool to assess people's openness and concerns about psychedelic therapy. Through surveys of 1,800+ participants, they identified key factors shaping acceptance: safety worries, therapeutic potential, and cultural beliefs. Results show growing support for clinical use while highlighting specific areas that need addressing to build public trust.
Abstract
Societal perspectives on psychedelics use in clinical context: Development of Concerns and Openness towards Psychedelic Scale (COPS).
Effect of esketamine on reducing postpartum pain and depression.
World journal of clinical cases – March 06, 2025
Summary
New mothers who receive esketamine during cesarean sections reported 40% less pain and showed significantly lower rates of postpartum depression. This innovative treatment combines pain relief with mood-stabilizing benefits. When administered during C-sections, esketamine provided superior postoperative analgesia while reducing depression risk in the critical postpartum period, helping mothers bond better with their newborns and recover faster.
Abstract
In this editorial, we comment on a recent article by Chen et al, that addressed the effect of intraoperative injection of esketamine on postoperati...